

Next generation vacuum-based cervical tenaculum, an atraumatic device that reduces the pain and bleeding associated with frequent gynaecological procedures

Julien Finci

ASPIVIX SA - Chief Technology Officer

Abstract

Unintended pregnancies are a global epidemic¹. They are associated with substantial costs to healthcare systems, social services as well as significant emotional distress to women, and their families². Worldwide, about 85 million pregnancies, representing 44 % of all annual pregnancies are unintended. ^{3,4} Of these pregnancies 50 % end in abortion, 12 % end in miscarriage, and 38 % result in unplanned births ⁵. In the US alone, the annual excess costs to the economy is about 11 billion US dollars⁶. Up to 100,000 maternal deaths could be avoided each year if women who did not want children used effective contraception.³ 40% of the unintended pregnancies are a result of contraceptive failure or incorrect use. ³ If contraception need was fully satisfied, 53 million unplanned pregnancies could be prevented.³ The Intrauterine Device (IUD) is considered the most cost-effective reversible contraceptive solution^{7,8,9}. Fear of severe pain during IUD placement remains a significant adoption barrier for women^{10,11,12}. Several attempts to reduce pain and bleeding have been reported in the literature such as changing the design of tenaculum¹³, applying anaesthetics, without much success ^{10,14}. A next-generation, patent protected vacuum-based cervical device that delivers the same manoeuvrability as the tenaculum without the reported patient trauma related to pain, bleeding and tissue tear would support IUD adoption¹⁵. Results from “First in Women” Trial in Switzerland are expected in 2H2020.



Speaker Publications:

1 Endorsed by ESC, FICO. “The Global Epidemic of Unintended Pregnancies; Impact and Possible Approaches to the Problem”.

2 World Contraception Day Coalition (WCD). “Global Perspectives on Unplanned Pregnancies”. <https://www.your-life.com/wcd>

3 Bearak J., Popinchalk A, Alkema L, et al. “Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014:

estimates from a Bayesian hierarchical model”. *Lancet Glob Health* 2018; 6: e380–89

4 World Health Organization. “The World Health Report 2005, Make Every Mother and Child Count”. Chapter 3. Not Every Pregnancy is

Welcomed, Planning Pregnancies Before They Even Happen. <https://www.who.int/whr/2005/en/>

5 Sedgh H, Singh S, Hussain R. “Intended and Unintended Pregnancies Worldwide in 2012 and Recent Trends”. *Studies In Family Planning*.2014;

45[3]: 301–314.

6 Sonfield, A, Kathryn K, Rachel B. et al. “The Public Costs of Births Resulting from Unintended Pregnancies: National and State-Level Estimates.”

Perspective on Sexual and Reproductive Health 43.2 (2011): 94-102

7 Trussell J. “Contraceptive Failure in the United States”. *Contraception* 2011;83:397–404

8 Winner B, Peipert JF, Zhao Q, et al. “Effectiveness of long-acting reversible contraception”. *NEJM* 2012 May 24; 366(21):1998-2007.

9 Trussell J, et al. “Cost Effectiveness of Contraceptives in the United States”. *Contraception*. Volume 79, Issue 1, January 2009, Pages 5-14

10 Lopez LM, Bernholc A, Zeng Y, et al. “Interventions for pain with intrauterine device insertion”, *Cochrane Database Syst Rev*. 2015 Jul 29; (7)

CD007373.

11 Bahamondes L, Mansour D, Fiala C, et al. "Practical Advice for Avoidance of Pain Associated with Insertion of Intrauterine Contraceptives". J

Fam Plann Reprod Health Care 2014;40:54–60.

12 Fiala C, Danielsson K, Tang OS, et al."Cervical priming with misoprostol prior to transcervical procedures". Int J Gyn &Obs 2007;99 (Suppl.

2):S168–S171

13 Doty N, MacIsaac L."Effect of an atraumatic vulsellum versus a single-tooth tenaculum on pain perception during intrauterine device insertion: a

randomized controlled trial". Contraception. 2015 Dec;92(6):567-71. doi: 10.1016/j.contraception.2015.05.009.

14 Bednarek PH, Creinin MD, Reeves MF, et al. "Prophylactic ibuprofen does not improve pain with IUD insertion: a randomized trial"

Contraception 91 (2015) 193–197. 15 ASPIVIX "Data on File" 2019.

Biography:

Julien Finci, is a Microtechnology & Photonics engineer graduated from the Ecole Polytechnique Fédérale de Lausanne (EPFL) in 2008 and a certified project manager (CAPM). Julien worked for over 8 years at Danaher, a global MedTech company, driving new technology development for non-invasive measurement of transcutaneous CO₂ in the blood. Since 2016, Julien has been leading R&D for ASPIVIX SA, a swiss-based, medical technology company dedicated to bringing innovation in the women's health space.

Presenting author details:

Full name: Julien Finci

Contact number:+41 76 327 87 97

Twitter account:NA

Linked In account: <https://ch.linkedin.com/in/julien-finci-a795021>

Session name/ number:

Category: (Oral presentation/ Poster presentation)